Years: 2020 – 2021
Training Site: Infectious Diseases Institute Mulago
Country: Uganda
Mentors: Kelly Dooley, MD, MPH, PhD; Christine Sekaggya-Wiltshire, MBChB, MMed
Title: “Role of pharmacogenomics in Dolutegravir serum drug levels among HIV/TB co-infected persons on rifampicin in a pharmacokinetic clinical trial”
Program Objectives:
Aim 1: To describe UGT 1A1 polymorphisms among HIV infected patients in Uganda receiving rifampicin.
Aim 2: To investigate the effect of UGT 1A1 polymorphisms on dolutegravir pharmacokinetics among HIV infected patients in Uganda receiving rifampicin.
NIH Support: FIC-AIDS
